Publications by authors named "Kim Horrigan"

Claim this Profile
A
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.
Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari, Kapil N Bhalla, Alfonso Quintás-Cardama, Kim Horrigan

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Kim Horrigan

Clin Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification and characterization of a STAT5 gene signature in hematologic malignancies.
Dmitriy Sonkin, Michael Palmer, Xianhui Rong, Kim Horrigan, Catherine H Regnier

Cancer Biomark· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis